Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FPR1 | P21462 | 6/20 | 0.42 |
| ▸ | FPR2 | P25090 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482507 | 1.00 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4ALDH1A1FPR1 | |
| SCHEMBL6482499 | 1.00 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4ALDH1A1FPR1 | |
| SCHEMBL18590502 | 0.84 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL18590503 | 0.84 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL18590508 | 0.84 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL18590507 | 0.84 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL15927585 | 0.82 | ALDH1A1 (0.33) | SLC6A3ALDH1A1TP53MDM2 | |
| SCHEMBL12525034 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAGAA | |
| SCHEMBL1904591 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAGAA | |
| SCHEMBL1901694 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032858-A1 | Novel heterocyclic compound and anti-inflamatory agent | NIPPON SODA CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1435353-A1 | NOVEL HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT | NIPPON SODA CO., LTD. (JP) | 2004-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032858-A1 | Novel heterocyclic compound and anti-inflamatory agent | TLR5, IRF3, IL4 | SLC6A3 4753/4885SLC6A2 4738/4885SLC6A4 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.